Skip to the answer

Buprenorphine Uses, Dosage, Side Effects and Interactions

Brand names
Butrans

Butrans was approved by the FDA in June 2010 as a skin patch. An FDA-approved generic with the same active ingredient is listed.

Belbuca

Belbuca was approved by the FDA in October 2015 as a buccal film. No generic is listed as buccal films, though generic buprenorphine is listed as injections, skin patches and sublingual tablets.

First generic of Belbuca: our estimate, January 2027

Sublocade

Sublocade was approved by the FDA in November 2017 as an injection. The FDA rates no generic as a substitute for it.

Buprenex

Buprenex is a buprenorphine brand from before 1982 that came as an injection. The FDA now lists it as discontinued; generic buprenorphine is still listed.

Brixadi

Brixadi was approved by the FDA in May 2023 as an injection. The FDA rates no generic as a substitute for it.

First generic of Brixadi: our estimate, July 2032

Buprenorphine is a partial opioid medicine used to treat opioid use disorder (opioid dependence) and to manage severe, persistent pain, depending on the product and form.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About BuprenorphineType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Buprenorphine in Short

  • Drug class Partial Opioid Agonist How the FDA classifies it
  • What it treatsBuprenorphine is used for two main purposes, and which one applies depends on the product. Opioid use disorder: Buprenorphine sublingual tablets (opioid dependence, preferred for induction), Sublocade and Brixadi (moderate to severe opioid use disorder) are used with counseling and psychosocial support.
  • How you get it Prescription only Controlled substance, Schedule III
  • Comes asSublingual tablet, skin patch, injection and buccal film
    Available strengths

    Sublingual tablet (under the tongue)

    • 2 mg
    • 4 mg
    • 8 mg
    • 12 mg

    Skin patch (through the skin)

    • 5 mcg/h
    • 7.5 mcg/h
    + 21 more strengthsShow fewer strengths

    Skin patch (through the skin)

    • 10 mcg/h
    • 15 mcg/h
    • 20 mcg/h

    Injection (into a muscle, into a vein, under the skin)

    • 8 mg/0.16 mL
    • 16 mg/0.32 mL
    • 24 mg/0.48 mL
    • 32 mg/0.64 mL
    • 64 mg/0.18 mL
    • 96 mg/0.27 mL
    • 100 mg
    • 128 mg/0.36 mL
    • 300 mg

    Injection (into a muscle, into a vein, under the skin), amount in each mL

    • 0.3 mg/mL
    • 0.324 mg/mL

    Buccal film (inside the cheek)

    • 75 mcg
    • 150 mcg
    • 300 mcg
    • 450 mcg
    • 600 mcg
    • 750 mcg
    • 900 mcg
    See forms and strengths
  • The FDA’s strongest warningBoxed warning on some forms On the patch, the injection and the forms held in the cheek. Read the warnings for your exact product.
  • What pharmacies pay
    • Generic$0.30 to $0.56 a tablet
    • Injections: no national price found
    + 3 more price detailsShow fewer price details
    • Skin patches, generic: $22.81 to $56.76 each
    • Skin patches, Butrans: $48.90 to $131.06 each
    • Buccal films, Belbuca: $7.54 to $18.59 each
    The pharmacy’s own cost, national average. Not your price See every price
  • Generic versionYes, FDA-approved Listed with the FDA, which does not mean every pharmacy stocks it

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Buprenorphine is a partial opioid (it switches on the brain’s opioid receptors only partway), a leading first-choice medicine for opioid use disorder and an option for severe, persistent pain when other treatments fall short; it has been on the U.S. market since about 1981, and FDA-approved generics are listed. Most people tolerate it reasonably well, and the side effects they notice most are nausea, constipation and headache, plus itchy or red skin under a patch. Watch above all for slowed or shallow breathing, a boxed warning risk alongside addiction and fatal accidental exposure in children, and one that climbs sharply with alcohol or sedating drugs.

Key Takeaways From the HelloPharmacist Team

  • Dissolve tablets whole under the tongue, wear each patch a full 7 days, and expect Sublocade or Brixadi as shots from your provider.
  • Keep naloxone, the overdose-reversal medicine, at home, and call 911 if someone on buprenorphine is breathing slowly or hard to wake.
  • Store every form locked up and out of children’s reach, because even one tablet, film or patch can kill a child.
  • Keep heating pads, electric blankets, hot tubs and saunas off a patch, and report a fever, because heat pushes more drug in.

How we write and review this content: our editorial policy

Buprenorphine by the Numbers

Strengths
27
across 4 forms
Makers and packagers
32
Earliest FDA record
1981
Rank by Medicaid prescriptions
#136 of 1,682 drugs
More prescriptions than 91% of the 1,682 drugs we measure
1.38 million prescriptions, Q1–Q4 2025
Other forms and routes

Patient Information Guide for Buprenorphine

What It’s Used For

Buprenorphine is used for opioid use disorder and for pain, depending on the product.

  • Sublingual tablets: opioid dependence, preferred for induction, with counseling and support.
  • Sublocade (subcutaneous): moderate to severe opioid use disorder.
  • Brixadi (subcutaneous): moderate to severe opioid use disorder.
  • Belbuca (buccal film): severe, persistent pain needing an opioid.
  • Butrans and buprenorphine skin patches: severe, persistent pain needing an opioid.
  • Buprenorphine hydrochloride injection: pain severe enough to need an opioid when other treatments are inadequate.

How It Works

Buprenorphine is a partial agonist at the mu-opioid receptor, so it activates the receptor only partly. It also blocks kappa-opioid receptors and acts on delta and ORL-1 (nociceptin) receptors. How much each action contributes to pain relief is unclear.

Drug Class

Drug Class

  • Partial Opioid Agonist
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • Partial Opioid Agonist

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)
  • Partial Opioid Agonists

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)

None listed for Buprenorphine in the FDA’s index.

From our Patient Information GuideBuprenorphine is a partial agonist at the mu-opioid receptor, so it activates the receptor only partly. It also blocks kappa-opioid receptors and acts on delta and ORL-1 (nociceptin) receptors. Read How Buprenorphine Works

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Buprenorphine in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Oripavine derivatives
  • Drugs used in opioid dependence

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Dosing depends on the product, so follow your prescriber and the label.

  • Sublingual tablets: once daily under the tongue, kept whole.
  • Skin patch: worn for 7 days at a time.
  • Belbuca: a film placed inside the cheek.
  • Sublocade and Brixadi: injected under the skin by a healthcare provider only.
  • Buprenorphine hydrochloride injection: given into a muscle or vein.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Buprenorphine Dissolved Under the Tongue

Opioid dependence
Adults dependent on heroin or other short-acting opioids · Induction Starting dose 2 to 4 mg
  • First dose only when objective and clear signs of moderate opioid withdrawal appear, not less than 4 hours after last opioid use
  • Initial day dosing may be given in 2 mg to 4 mg increments
  • In one study 8 mg on Day 1 and 16 mg on Day 2
Adults dependent on methadone or other long-acting opioids · Induction First dose only when objective and clear signs of moderate opioid withdrawal appear, and generally not less than 24 hours after last long-acting opioid

Good to know

Withdrawal more likely with methadone doses above 30 mg

Adults · Maintenance Usual dose 16 mg once a day

Step by step

  1. Adjust in increments/decrements of 2 mg or 4 mg buprenorphine
  2. Recommended dose after induction 16 mg buprenorphine per day
  3. Generally in the range of 4 mg to 24 mg buprenorphine per day, single daily dose
  4. Dosages higher than 24 mg daily have not been investigated in randomized clinical trials
Adults with severe liver problems Consider reducing the starting and titration incremental dose by half

Good to know

Monitor for toxicity or overdose

See the Full Dosing Instructions on DailyMed →

Brixadi

Opioid use disorder
Adults not currently taking buprenorphine · First week Starting dose 16 mg Usual dose 24 mg once a week Highest dose 32 mg in the first week

Step by step

  1. Test dose of transmucosal buprenorphine 4 mg, then Brixadi (weekly) 16 mg
  2. Additional 8 mg within 3 days to reach 24 mg; if needed an additional 8 mg after at least 24 hours for a total weekly dose of 32 mg
Adults taking sublingual buprenorphine 6 mg or less daily Usual dose 8 mg once a week
  • Brixadi (weekly) 8 mg
  • Brixadi (monthly) --
Adults taking sublingual buprenorphine 8-10 mg daily Usual dose 16 mg once a week

Step by step

  1. Brixadi (weekly) 16 mg
  2. Brixadi (monthly) 64 mg
Adults taking sublingual buprenorphine 12-16 mg daily Usual dose 24 mg once a week

Step by step

  1. Brixadi (weekly) 24 mg
  2. Brixadi (monthly) 96 mg
Adults taking sublingual buprenorphine 18-24 mg daily Usual dose 32 mg once a week

Step by step

  1. Brixadi (weekly) 32 mg
  2. Brixadi (monthly) 128 mg
Adults switching from weekly to monthly Brixadi · 16 mg Usual dose 64 mg once a month
  • Brixadi (monthly) 64 mg
Adults switching from weekly to monthly Brixadi · 24 mg Usual dose 96 mg once a month
  • Brixadi (monthly) 96 mg
Adults switching from weekly to monthly Brixadi · 32 mg Usual dose 128 mg once a month
  • Brixadi (monthly) 128 mg

See the Full Dosing Instructions on DailyMed →

Buprenorphine Injection

Pain
Adults and children over 12 years old Starting dose 0.3 mg every 6 hours as needed

Step by step

  1. 1 mL (0.3 mg buprenorphine) by deep intramuscular or slow (over at least 2 minutes) intravenous injection at up to 6-hour intervals, as needed
  2. May repeat once (up to 0.3 mg) 30 to 60 minutes after initial dose
  3. Single doses up to 0.6 mg I.M. only in adults not high risk

Good to know

High-risk patients: limit to minimum required

Children 2 to 12 years old 2-6 micrograms/kg of body weight every 4-6 hours

Good to know

No dose recommended below age two years; no repeat dose at 30-60 minutes

See the Full Dosing Instructions on DailyMed →

Sublocade

Opioid use disorder
Adults not already taking buprenorphine · Starting and maintenance Starting dose 300 mg Usual dose 100 mg once a month

Step by step

  1. Initial dose of 4 mg transmucosal buprenorphine
  2. Injection #1 300 mg
  3. Injection #2 300 mg (as early as 1 week and up to 1 month later)
  4. Then maintenance 100 mg monthly

Good to know

Maintenance 300 mg monthly may be considered if satisfactory response not shown

Opioid use disorder, transition from transmucosal buprenorphine 8 – 24 mg/day Starting dose 300 mg Usual dose 100 mg once a month

Step by step

  1. Injection #1 300 mg
  2. Injection #2 300 mg
  3. Maintenance 100 mg

Good to know

Those on 8 mg to 18 mg daily may receive 100 mg as second dose if symptoms controlled

See the Full Dosing Instructions on DailyMed →

Buprenorphine Skin Patch

Severe, ongoing pain
Adults taking 30 mg or less oral morphine equivalent daily · Starting dose Starting dose 5 mcg/hour patch for 7 days
  • 5 mcg/hour patch, worn for 7 days
Adults taking 30 mg to 80 mg oral morphine equivalent daily · Starting dose Starting dose 10 mcg/hour patch for 7 days
  • 10 mcg/hour patch, worn for 7 days
Good to Know for Every Dose

Wait a minimum of 3 weeks before using same site

See the Full Dosing Instructions on DailyMed →

Buprenorphine Dissolved in the Cheek

Severe, ongoing pain
Adults taking less than 30 mg oral MSE · Starting dose Starting dose 75 mcg once a day or every 12 hours
  • Belbuca 75 mcg once daily or every 12 hours
Adults taking 30 mg to 89 mg oral MSE · Starting dose Starting dose 150 mcg every 12 hours
  • Belbuca 150 mcg every 12 hours
Adults taking 90 mg to 160 mg oral MSE · Starting dose Starting dose 300 mcg every 12 hours
  • Belbuca 300 mcg every 12 hours
Adults taking more than 160 mg oral MSE Consider alternate analgesic

See the Full Dosing Instructions on DailyMed →

Side Effects

Common side effects with the buprenorphine patch include:

Common side effects

  • Nausea
  • Headache
  • Dizziness
  • Constipation
  • Sleepiness
  • Vomiting
  • Dry mouth
  • Itching, redness or rash at the patch site (skin patch)

When to get medical help

  • Slow or shallow breathing, extreme sleepiness, or trouble waking up: call 911 right away
  • Suspected overdose, including accidental exposure in a child: get emergency help immediately
  • Severe skin reaction at the patch site, such as burning, discharge or blisters: report it promptly
  • Signs of an allergic reaction, such as swelling or trouble breathing
  • Fainting or severe lightheadedness
  • Pain that gets worse or becomes more sensitive while on the medicine
  • Signs of serotonin syndrome if taken with other serotonergic drugs
  • Withdrawal symptoms in a newborn if used for a long time in pregnancy

Warnings and Precautions

  • Slowed breathing can be life-threatening, especially when starting or after a dose increase.
  • Addiction, abuse and misuse can happen even at prescribed doses.
  • Accidental exposure, especially in children, can be fatal.
  • Alcohol and sedating drugs greatly raise the risk of coma and death.
  • Heat or fever can raise drug levels from the patch.
  • Long-term use in pregnancy can cause newborn withdrawal.
  • Opioids can sometimes make pain worse (hyperalgesia).

Interactions

Several drugs can change how buprenorphine works or raise its risks.

  • Alcohol, benzodiazepines, gabapentinoids and other sedatives: extreme sleepiness and slowed breathing.
  • CYP3A4 inhibitors (ketoconazole, erythromycin, ritonavir, atazanavir): higher buprenorphine levels.
  • CYP3A4 inducers (rifampin, carbamazepine, phenytoin, phenobarbital): lower levels and possible withdrawal.
  • MAO inhibitors: Sublocade is not recommended within 14 days.
  • Serotonergic drugs (SSRIs, SNRIs, triptans, tramadol): risk of serotonin syndrome.
  • Muscle relaxants: added breathing risk.
  • Diuretics: may work less well.

Interactions Listed in the FDA-Approved Label

From the Buprenorphine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Benzodiazepines and other CNS depressants For example: alcohol
    What happensIncreases the risk of respiratory depression, profound sedation, coma, and death.
    What to doCessation is preferred in most cases; if concomitant use is warranted, strongly consider prescribing naloxone.
  • CYP3A4 inhibitors For example: ketoconazole, erythromycin, ritonavir
    What happensCan increase buprenorphine plasma concentration, resulting in increased or prolonged opioid effects.
    What to doMonitor for signs and symptoms of over-medication; it may be necessary to remove the depot.
  • CYP3A4 inducers For example: rifampin, carbamazepine, phenytoin, phenobarbital
    What happensMay increase clearance, lowering buprenorphine levels, causing lack of efficacy or abstinence syndrome.
    What to doMonitor for withdrawal; transition to adjustable-dose buprenorphine if needed.
  • Antiretrovirals: NNRTIs (efavirenz, nevirapine, etravirine, delavirdine)
    What happensPharmacokinetic interactions shown with sublingual buprenorphine did not result in significant pharmacodynamic effects.
    What to doMonitor for increase or decrease in therapeutic effects.
  • Antiretrovirals: protease inhibitors (atazanavir, ritonavir)
    What happensAtazanavir with or without ritonavir elevated buprenorphine levels and increased sedation; nelfinavir, lopinavir/ritonavir, ritonavir had little effect.
    What to doMonitor for over-medication; it may be necessary to remove the depot.
  • Antiretrovirals: NRTIs
    What happensDo not appear to induce or inhibit the P450 pathway, so no interactions are expected.
    What to doNone
  • Serotonergic drugs (SSRIs, SNRIs, TCAs, triptans, tramadol, etc.)
    What happensConcomitant use with opioids has resulted in serotonin syndrome.
    What to doMonitor carefully for serotonin syndrome, especially at initiation and dose adjustment.
  • Monoamine oxidase inhibitors (MAOIs)
    What happensMay manifest as serotonin syndrome or opioid toxicity.
    What to doUse not recommended with MAOIs or within 14 days of stopping them.
  • Muscle relaxants
    What happensBuprenorphine may enhance neuromuscular blocking action and increase respiratory depression.
    What to doMonitor for respiratory depression and decrease the muscle relaxant dose as necessary; strongly consider naloxone.
  • Diuretics
    What happensOpioids can reduce diuretic efficacy by inducing release of antidiuretic hormone.
    What to doMonitor for diminished diuresis and blood pressure effects; increase the diuretic dose as needed.
Read the label’s full interactions text

7 DRUG INTERACTIONS Table 3 includes clinically significant drug interactions with Buprenorphine Sublingual Tablets. Table 3. Clinically Significant Drug Interactions with Buprenorphine Sublingual Tablets Benzodiazepines or other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. Intervention: Cessation of benzodiazepines or other CNS depressants is preferred in most cases of concomitant use. In some cases, monitoring in a higher level of care for taper may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or CNS depressant or decreasing to the lowest effective dose may be appropriate. Before co-prescribing benzodiazepines for anxiety or insomnia, ensure that patients are appropriately diagnosed and consider alternative medications and non-pharmacologic treatments. If concomitant use is warranted, strongly consider recommending or prescribing an opioid overdose reversal agent, as is recommended for all patients on buprenorphine treatment for opioid use disorder. Examples: Benzodiazepines and other sedative/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), other opioids, alcohol. Inhibitors of CYP3A4 Clinical Impact: The concomitant use of buprenorphine and CYP3A4 inhibitors can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of Buprenorphine Sublingual Tablets is achieved.

Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Not for people with significant breathing problems, a bowel blockage or an allergy to buprenorphine (patch labeling).
  • Tell your prescriber about asthma or lung disease.
  • Mention any history of substance misuse or mental illness.
  • Severe liver problems may need a lower starting dose.
  • Older adults need monitoring for sedation and slowed breathing.
  • Discuss pregnancy; buprenorphine passes into breast milk.

Overdose

Overdose can cause slowed breathing, deep sleepiness progressing to coma, limp muscles, cold clammy skin and pinpoint pupils. Call 911 right away. For the patch, remove it immediately; monitoring for at least 24 hours may be needed. Naloxone may be less effective against buprenorphine, so emergency care is essential.

How Your Body Processes It

Each buprenorphine patch delivers medicine for 7 days, reaching steady levels by about day 3. Drug is usually detectable about 17 hours after application. Buprenorphine is processed mainly by the liver enzyme CYP3A4 and cleared through bile into stool and through urine. After a patch is removed, levels fall about 50% in 12 hours.

Storage

Store Buprenorphine Sublingual Tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home .

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Buprenorphine: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Buprenorphine — the kind of thing our pharmacy team would talk through with you at the counter.

What is buprenorphine used for?

It depends on the product. Sublingual tablets, Sublocade and Brixadi treat opioid dependence. Belbuca, Butrans, patches and the injection treat severe pain that needs an opioid.

How should I take it?

Follow your label exactly. Sublingual tablets dissolve under the tongue once daily and must not be chewed or swallowed. Patches stay on for 7 days, and injections are given by a provider.

What side effects should I expect?

Nausea, headache, dizziness, constipation, sleepiness and dry mouth are common. With patches, you may get itching or redness at the site. Call for help if breathing slows or you can't stay awake.

Can I drink alcohol or take sleep or anxiety medicines with it?

No, not without your prescriber's guidance. Alcohol, benzodiazepines and other sedatives can cause dangerous sedation, slowed breathing, coma and death.

Can I use a heating pad over my patch?

No. Heat can make your body absorb more medicine and cause overdose. Also avoid saunas, hot tubs and electric blankets over the patch, and tell your prescriber if you have a fever.

Is it safe in pregnancy?

Talk to your prescriber. Long-term use can cause withdrawal in newborns, so doctors will plan for that. Untreated opioid addiction in pregnancy also carries risks.

Is buprenorphine available over the counter?

No. Buprenorphine is a prescription medicine: every buprenorphine product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

Is buprenorphine a controlled substance?

Yes — buprenorphine is a federally controlled substance (Schedule III) in the United States, so how it is prescribed, refilled and dispensed is regulated by the DEA.

When was buprenorphine first available?

The earliest FDA record we hold for buprenorphine is from 1981: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when buprenorphine was first used.

Who makes buprenorphine?

32 companies currently list buprenorphine products in the FDA's NDC Directory, including BioDelivery Sciences International Inc, Braeburn Inc., Bryant Ranch Prepack. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

What is the brand name of buprenorphine?

Buprenorphine is the generic name. Its brand names are Butrans, Belbuca, Sublocade, Buprenex and Brixadi. Generic versions are listed under the name buprenorphine.

What is the generic name of Butrans?

The generic name of Butrans is buprenorphine. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is buprenorphine?

Buprenorphine belongs to the drug class Partial Opioid Agonist, its established pharmacologic class on the FDA label.

Is there a generic version of buprenorphine?

Yes. FDA-approved generic versions of buprenorphine are listed in the FDA's National Drug Code Directory. A listing does not prove that every pharmacy stocks one, so your pharmacy can tell you which version it carries.

What strengths does buprenorphine come in?

Buprenorphine is listed in the FDA's National Drug Code Directory in these forms and strengths. Sublingual tablet (under the tongue): 2 mg, 4 mg, 8 mg and 12 mg. Skin patch (through the skin): 5 mcg/h, 7.5 mcg/h, 10 mcg/h, 15 mcg/h and 20 mcg/h. Injection (into a muscle, into a vein, under the skin): 8 mg/0.16 mL, 16 mg/0.32 mL, 24 mg/0.48 mL, 32 mg/0.64 mL, 64 mg/0.18 mL, 96 mg/0.27 mL, 100 mg, 128 mg/0.36 mL and 300 mg. Injection (into a muscle, into a vein, under the skin), amount in each mL: 0.3 mg/mL and 0.324 mg/mL. Buccal film (inside the cheek): 75 mcg, 150 mcg, 300 mcg, 450 mcg, 600 mcg, 750 mcg and 900 mcg. A listing does not mean every pharmacy stocks every strength.

How much does buprenorphine cost?

What you pay depends on your insurance, your pharmacy and the strength you take. As a benchmark, pharmacies paid a national average of $0.30 to $0.56 per generic sublingual tablet across 2 strengths, $22.81 to $56.76 each for the generic skin patch across 5 strengths, $48.90 to $131.06 each for the skin patch of brand-name Butrans across 5 strengths and $7.54 to $18.59 each for the buccal film of brand-name Belbuca across 7 strengths as of November 18, 2026 (CMS's NADAC survey). That is the pharmacy's own cost for the medicine, not the price at the counter. No national price was found for buprenorphine injections. The pharmacy prices section of this page lists every strength priced.

Is there a buprenorphine shortage?

No. Buprenorphine is not on the FDA's drug shortage list as of Nov 22, 2026. A single pharmacy can still run short for a while without a national shortage, and your pharmacist can tell you what they are seeing.

Where can I read the buprenorphine prescribing information (package insert)?

The full FDA-approved prescribing information for buprenorphine, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from SpecGx LLC's, revised Jun 5, 2026, and links to it on DailyMed.

Is buprenorphine gluten free?

No buprenorphine label we read lists an ingredient made from wheat, barley or rye, the grains that carry gluten, and none names a starch, dextrin or maltodextrin without saying where it comes from. We read the FDA labels of 106 buprenorphine products from 31 companies. A label lists ingredients; it is not a gluten test, so we cannot promise that any product has no gluten. If you have celiac disease, ask the company for a written gluten statement. Our Inactive Ingredient Checker shows each company's buprenorphine by strength and NDC, and whether its label lists a gluten source, lactose, dyes or any other inactive ingredient. See buprenorphine inactive ingredients by company

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Buprenorphine

Skip the scrolling. Ask in your own words and get an answer from Buprenorphine’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Buprenorphine’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Buprenorphine on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for Buprenorphine Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Buprenorphine Forms and Strengths (How It Comes)

Buprenorphine comes in 4 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Buprenorphine inactive ingredients by manufacturer.

Sublingual tablet

Under the tongue
How this form is used
What it may be used for
  • Buprenorphine sublingual tablets are used for opioid dependence and are preferred for induction, along with counseling and support.
Important instructions
  • Buprenorphine sublingual tablets are taken under the tongue as a single daily dose.
  • Buprenorphine HCl sublingual tablets must be kept whole: don't cut, chew or swallow them.
  • Buprenorphine sublingual tablets do not contain naloxone and are preferred only during induction.
Available strengths 4 strengths
51 FDA-listed product records ⓘ

Skin patch

Through the skin
Brands Butrans (2010)
How this form is used
What it may be used for
  • Butrans is used for severe, persistent pain that needs an opioid and can't be managed with other options.
  • Buprenorphine transdermal system is used for severe, persistent pain; it is not for as-needed use.
Important instructions
  • Butrans and buprenorphine transdermal system patches should be prescribed only by professionals experienced with extended-release opioids.
  • Each buprenorphine transdermal system patch delivers medicine for 7 days.
  • Avoid heating pads, electric blankets, saunas and hot tubs on the patch area.
Available strengths 5 strengths
35 FDA-listed product records ⓘ

Injection

Into a muscle · Into a vein · Under the skin
Brands Sublocade (2017) Buprenex (before 1982, discontinued) Brixadi (2023)
How this form is used
What it may be used for
  • Sublocade is used for moderate to severe opioid use disorder, along with counseling and support.
  • Brixadi is used for moderate to severe opioid use disorder, along with counseling and support.
  • Buprenorphine hydrochloride injection is used for pain severe enough to need an opioid when other treatments are inadequate.
Important instructions
  • Sublocade is prepared and given only by a healthcare provider, as an injection under the skin.
  • Brixadi is given only by a healthcare provider, as a slow injection under the skin.
  • Brixadi weekly and monthly are different formulations, and their doses can't be combined.
  • Buprenorphine hydrochloride injection is given into a muscle or vein.
Available strengths 11 strengths
Show 5 more strengths Show fewer strengths
14 FDA-listed product records ⓘ

Buccal film

Inside the cheek
Brands Belbuca (2015)
How this form is used
What it may be used for
  • Belbuca is used for severe, persistent pain that needs an opioid and can't be managed with other options, including immediate-release opioids.
  • Belbuca is not for as-needed pain relief.
Important instructions
  • Belbuca should be prescribed only by professionals experienced with extended-release opioids.
  • Belbuca is used at the lowest effective dose for the shortest time.
  • Breathing problems can occur at any time with Belbuca, especially at the start or after a dose increase.
Available strengths 7 strengths
Show 1 more strength Show fewer strengths
7 FDA-listed product records ⓘ

Buprenorphine on the U.S. Market: Products, Makers and Brands

How Buprenorphine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

32 companies list 107 Buprenorphine product records with the FDA, mostly as sublingual tablet, skin patch, injection; the earliest marketing or approval year on record is 1981. Brand names in the directory today include Butrans, Belbuca, Sublocade and 1 more; the rest are generics.

4
Dose forms ⓘ
32
Labelers (makers, repackagers, distributors)
5
Brand names ⓘ
107
FDA-listed product records ⓘ
1981
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (45) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

BioDelivery Sciences International Inc7%
Braeburn Inc.7%
Bryant Ranch Prepack7%
Rhodes Pharmaceuticals LLC7%
Clinical Solutions Wholesale, LLC6%
Amneal Pharmaceuticals NY LLC5%
Other makers64%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How Widely Buprenorphine Is Used (Medicaid Data)

How many Buprenorphine prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

1,379,027
Medicaid prescriptions filled (Q1–Q4 2025)
$984.4M paid by Medicaid, before rebates

How commonly is Buprenorphine prescribed? Of the 1,682 medications we measure, Buprenorphine ranks #136 by Medicaid prescriptions — more than 92% of them.

Where Buprenorphine ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Buprenorphine product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

The 8 mg sublingual tablet is the most-dispensed Buprenorphine product — about 46% of these Medicaid prescriptions.

buprenorphine 8 MG Sublingual Tablet Most dispensed

630,724 Medicaid prescriptions (Q1–Q4 2025) 46% of Buprenorphine prescriptions shown $29.9M paid by Medicaid, before rebates ≈ $47 per prescription, before rebates

8 of 85 listed NDCs had Medicaid claims. RxNorm 351265

1.5 ML buprenorphine 200 MG/ML Prefilled Syringe

221,541 Medicaid prescriptions (Q1–Q4 2025) 16% of Buprenorphine prescriptions shown $441.7M paid by Medicaid, before rebates ≈ $1,994 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims. RxNorm 1996192

0.5 ML buprenorphine 200 MG/ML Prefilled Syringe

113,583 Medicaid prescriptions (Q1–Q4 2025) 8% of Buprenorphine prescriptions shown $230.4M paid by Medicaid, before rebates ≈ $2,029 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims. RxNorm 1996184

buprenorphine 2 MG Sublingual Tablet

106,539 Medicaid prescriptions (Q1–Q4 2025) 8% of Buprenorphine prescriptions shown $3M paid by Medicaid, before rebates ≈ $28 per prescription, before rebates

8 of 65 listed NDCs had Medicaid claims. RxNorm 351264

0.36 ML buprenorphine 356 MG/ML Prefilled Syringe

57,502 Medicaid prescriptions (Q1–Q4 2025) 4% of Buprenorphine prescriptions shown $94.5M paid by Medicaid, before rebates ≈ $1,644 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 2639043

0.27 ML buprenorphine 356 MG/ML Prefilled Syringe

35,529 Medicaid prescriptions (Q1–Q4 2025) 3% of Buprenorphine prescriptions shown $58.9M paid by Medicaid, before rebates ≈ $1,658 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 2639041

168 HR buprenorphine 0.01 MG/HR Transdermal System

29,227 Medicaid prescriptions (Q1–Q4 2025) 2% of Buprenorphine prescriptions shown $7.5M paid by Medicaid, before rebates ≈ $257 per prescription, before rebates

5 of 11 listed NDCs had Medicaid claims. RxNorm 904870

168 HR buprenorphine 0.02 MG/HR Transdermal System

27,738 Medicaid prescriptions (Q1–Q4 2025) 2% of Buprenorphine prescriptions shown $12.5M paid by Medicaid, before rebates ≈ $451 per prescription, before rebates

6 of 11 listed NDCs had Medicaid claims. RxNorm 904876

168 HR buprenorphine 0.015 MG/HR Transdermal System

21,299 Medicaid prescriptions (Q1–Q4 2025) 2% of Buprenorphine prescriptions shown $9.2M paid by Medicaid, before rebates ≈ $432 per prescription, before rebates

5 of 11 listed NDCs had Medicaid claims. RxNorm 1432969

0.18 ML buprenorphine 356 MG/ML Prefilled Syringe

20,591 Medicaid prescriptions (Q1–Q4 2025) 1% of Buprenorphine prescriptions shown $33.5M paid by Medicaid, before rebates ≈ $1,628 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 2639036

168 HR buprenorphine 0.005 MG/HR Transdermal System

16,459 Medicaid prescriptions (Q1–Q4 2025) 1% of Buprenorphine prescriptions shown $2.8M paid by Medicaid, before rebates ≈ $169 per prescription, before rebates

5 of 12 listed NDCs had Medicaid claims. RxNorm 904880

buprenorphine 0.3 MG Buccal Film

10,931 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine prescriptions shown $6.9M paid by Medicaid, before rebates ≈ $634 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 1716065

0.48 ML buprenorphine 50 MG/ML Prefilled Syringe

10,635 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine prescriptions shown $5.5M paid by Medicaid, before rebates ≈ $516 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 2639031

168 HR buprenorphine 0.0075 MG/HR Transdermal System

10,566 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine prescriptions shown $2.7M paid by Medicaid, before rebates ≈ $252 per prescription, before rebates

5 of 9 listed NDCs had Medicaid claims. RxNorm 1542997

0.64 ML buprenorphine 50 MG/ML Prefilled Syringe

10,557 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine prescriptions shown $5.5M paid by Medicaid, before rebates ≈ $520 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 2639033

buprenorphine 0.45 MG Buccal Film

9,203 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine prescriptions shown $7.9M paid by Medicaid, before rebates ≈ $862 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims. RxNorm 1716069

buprenorphine 0.9 MG Buccal Film

8,820 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine prescriptions shown $9M paid by Medicaid, before rebates ≈ $1,024 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 1716086

buprenorphine 0.15 MG Buccal Film

8,800 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine prescriptions shown $3.5M paid by Medicaid, before rebates ≈ $397 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 1716057

buprenorphine 0.6 MG Buccal Film

8,076 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine prescriptions shown $7.5M paid by Medicaid, before rebates ≈ $927 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 1716073

0.32 ML buprenorphine 50 MG/ML Prefilled Syringe

5,871 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine prescriptions shown $3M paid by Medicaid, before rebates ≈ $507 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 2639029

0.16 ML buprenorphine 50 MG/ML Prefilled Syringe

5,040 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine prescriptions shown $2.5M paid by Medicaid, before rebates ≈ $488 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 2639021

buprenorphine 0.75 MG Buccal Film

4,849 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine prescriptions shown $4.8M paid by Medicaid, before rebates ≈ $989 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 1716081

buprenorphine 0.075 MG Buccal Film

4,536 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine prescriptions shown $1.7M paid by Medicaid, before rebates ≈ $373 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 1716077

1 ML buprenorphine 0.3 MG/ML Injection

384 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine prescriptions shown $5,419 paid by Medicaid, before rebates ≈ $14 per prescription, before rebates

1 of 8 listed NDCs had Medicaid claims. RxNorm 238129

1 ML buprenorphine 0.3 MG/ML Cartridge

27 Medicaid prescriptions (Q1–Q4 2025) <1% of Buprenorphine prescriptions shown

1 of 2 listed NDCs had Medicaid claims. RxNorm 1655032

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 60 of the 249 listed Buprenorphine NDCs had Medicaid claims.

Compare Buprenorphine Products

A representative set of FDA-listed product records for Buprenorphine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 107 of 107 products — FDA National Drug Code Directory. See every product, package size and price: browse all 107 Buprenorphine NDCs →

Buprenorphine Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list 7 Buprenorphine recalls since July 2021. Five of them are still ongoing or began in the last six months and are listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.

Ongoing Class II Sep 8, 2026 · Par Health USA, LLC
Crystallization
  • Buprenorphine Hydrochloride, Injection 0.3 mg/mL, Rx Only, 5 x 1 mL Single Dose Vials, Manufactured for: Endo USA, Malvern, PA, NDC 42023-179-05 Lots: Lot#:83912, Exp Date 10/2026 Lot#:84234, Exp Date 11/2026 Lot#:84990, Exp Date 11/2026 Lot#:85003, Exp Date 12/2026 Lot#:86443, Exp Date 01/2027 Lot#:89909, Exp Date 05/2027 FDA record D-0876-2026 →
Ongoing Class III Aug 19, 2026 · American Health Packaging
Labeling: Label Mix-up
  • Buprenorphine Sublingual Tablets (C-III), 2 mg, 30 Tablets (3x10), Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC#: 60687-481-21, (Individual Dose NDC: 60687-481… Lots: Lot # 1030023, Exp Date: 06/30/2027. FDA record D-0840-2026 →
Ongoing Class II Jun 12, 2026 · Par Health USA, LLC
Crystallization; identified as Buprenorphine free base
  • Buprenorphine HCl, CIII, Injection, 0.3 mg/mL, 5 x 1 mL Single Dose Vials per Carton, Rx Only, For Intramuscular or Intravenous use, Manufactured for: Endo USA, Malvern, PA 19355, NDC 42023-179-05 Lots: Lot #: 82886, exp 09/30/2026; 89646, exp 05/31/2027 FDA record D-0596-2026 →
Ongoing Class II Mar 13, 2026 · ENDO USA, Inc.
Crystallization; identified as Buprenorphine free base
  • Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05. Lots: Lot #: 84132, Exp 02/28/2027; 87693, Exp 03/31/2027 FDA record D-0527-2026 →
Ongoing Class II May 20, 2024 · Pfizer Inc.
Lack of Assurance of Sterility-The potential for incomplete crimp seals.
  • Buprenorphine Hydrochloride Injection, 0.3 mg base/mL, 1 mL Single-dose Carpuject, Sterile Cartridge Unit with Luer Lock, For Intramuscular or Intravenous Use, Rx Only, Distributed by Hospira, Inc.,… Lots: Lot#: HJ3965; Exp 2024/09 Lot#: HJ8546; Exp 2024/10 FDA record D-0564-2024 →
Class II May 3, 2023 · Terminated · SUN PHARMACEUTICAL INDUSTRIES INC
CGMP Deviations
  • Buprenorphine Sublingual Tablets, 8 mg, 30 count-bottles, Rx only, Manufactured by: Sun Pharma, NDC 62756-460-83. Lots: Lot #: DND1515A, Exp 08/24 FDA record D-0869-2023 →
Class II Nov 9, 2021 · Terminated · PAR Sterile Products LLC
Crystallization; identified as Buprenorphine free base
  • Buprenorphine HCl, Injection, 0.3mg/mL, For Intramuscular or Intravenous Use, Rx Only, 1mL Single Dose Vial, (supplied in packages of 5 vials) Distributed by Par Pharmaceutical, Chestnut Ridge, NY 10… Lots: Lot No: 343716, Exp. Date: 11/2021; Lot No: 350565, Exp. Date: 07/2022; Lot No: 26921, Exp. Date: 07/2022; Lot No: 36227, Exp. Date: 02/2023 FDA record D-0087-2024 →

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Buprenorphine in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
9
Strengths
31
Forms in current FDA listings
7 of 9
In current FDA listings No current FDA listing
Ingredient (IN) Buprenorphine RxCUI 1819
  1. Dose form (SCDF) Buccal Film RxCUI 1716056
    In current FDA listings
    Its 7 strengths (SCD)
  2. Dose form (SCDF) Cartridge RxCUI 1655031
    In current FDA listings
    Its strength (SCD)
  3. Dose form (SCDF) Drug Implant RxCUI 1797649
    No current FDA listing
  4. Dose form (SCDF) Injectable Solution RxCUI 379112
    In current FDA listings
    Its strength (SCD)
    • 1.8 mg/mL RxCUI 1594650
  5. Dose form (SCDF) Injection RxCUI 1729358
    In current FDA listings
    Its strength (SCD)
  6. Dose form (SCDF) Prefilled Syringe RxCUI 1996183
    In current FDA listings
  7. Dose form (SCDF) Sublingual Tablet RxCUI 371161
    In current FDA listings
    Its 6 strengths (SCD)
    • 0.2 mg RxCUI 246474
    • 0.4 mg RxCUI 250426
    • 2 mg RxCUI 351264
    • 4 mg RxCUI 2747482
    • 8 mg RxCUI 351265
    • 12 mg RxCUI 2747481
  8. Dose form (SCDF) Topical Solution RxCUI 2599845
    No current FDA listing
    Its strength (SCD)
    • 20 mg/mL RxCUI 2599846
  9. Dose form (SCDF) Transdermal System RxCUI 1806212
    In current FDA listings
    Its 5 strengths (SCD)

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

What Buprenorphine Costs Pharmacies (NADAC Benchmark)

What pharmacies pay to buy Buprenorphine: the national average from CMS’s weekly NADAC survey, as of Nov 18, 2026. It is the pharmacy’s cost, not your price at the counter.

No national price was found for Buprenorphine injections, so the prices below are for the sublingual tablets, skin patches and buccal films only.

How the Pharmacy Price Has Changed

Pick a form, the generic or the brand, and a strength to see how its price has changed since Nov 2023.

Form
Version
Strength

At this strength, Butrans costs pharmacies $48.90 each.

For the generic BUPRENORPHINE 5 mcg/h skin patch, pharmacies paid an average of $22.81 each as of Nov 18, 2026, up 3% from $22.15 a year earlier. At this strength, Butrans costs pharmacies $48.90 each.

What pharmacies pay now
$22.81
each, as of Nov 18, 2026
Last 4 weeks
Down 5.3%
from $24.09 on Oct 21, 2026
Last 12 months
Up 3%
from $22.15 on Nov 19, 2025
Lowest and highest since Nov 2023
$19.02 to $37.97
each

Each step is one weekly survey. Arrow keys on the chart move week by week.
See the numbers, month by month
Generic BUPRENORPHINE 5 mcg/h skin patch: the average pharmacy price each, the last survey of each month
MonthPharmacy price
Nov 2026$22.81
Oct 2026$24.09
Sep 2026$23.45
Aug 2026$23.82
Jul 2026$22.92
Jun 2026$23.97
May 2026$22.80
Apr 2026$22.38
Mar 2026$20.83
Feb 2026$20.93
Jan 2026$20.89
Dec 2025$22.58
Nov 2025$22.15
Oct 2025$22.15
Sep 2025$21.25
Aug 2025$21.45
Jul 2025$21.52
Jun 2025$21.29
May 2025$21.91
Apr 2025$20.97
Mar 2025$21.39
Feb 2025$20.08
Jan 2025$20.81
Dec 2024$20.74
Nov 2024$21.61
Oct 2024$21.72
Sep 2024$23.32
Aug 2024$22.20
Jul 2024$19.32
Jun 2024$24.96
May 2024$19.02
Apr 2024$21.87
Mar 2024$26.35
Feb 2024$26.82
Jan 2024$29.50
Dec 2023$32.00
Nov 2023$37.97
See all 19 prices in a table
FormStrengthVersion What pharmacies pay
Skin patch · Transdermal BUPRENORPHINE 5 mcg/h Generic $22.81 each NDC details & price history
Skin patch · Transdermal BUPRENORPHINE 5 mcg/h Butrans (brand) $48.90 each NDC details & price history
Skin patch · Transdermal BUPRENORPHINE 7.5 mcg/h Generic $37.41 each NDC details & price history
Skin patch · Transdermal BUPRENORPHINE 7.5 mcg/h Butrans (brand) $68.74 each NDC details & price history
Skin patch · Transdermal BUPRENORPHINE 10 mcg/h Generic $32.54 each NDC details & price history
Skin patch · Transdermal BUPRENORPHINE 10 mcg/h Butrans (brand) $73.55 each NDC details & price history
Skin patch · Transdermal BUPRENORPHINE 15 mcg/h Generic $48.00 each NDC details & price history
Skin patch · Transdermal BUPRENORPHINE 15 mcg/h Butrans (brand) $124.60 each NDC details & price history
Skin patch · Transdermal BUPRENORPHINE 20 mcg/h Generic $56.76 each NDC details & price history
Skin patch · Transdermal BUPRENORPHINE 20 mcg/h Butrans (brand) $131.06 each NDC details & price history
Buccal film · Buccal 75 mcg Belbuca (brand) $7.54 each NDC details & price history
Buccal film · Buccal 150 mcg Belbuca (brand) $7.55 each NDC details & price history
Buccal film · Buccal 300 mcg Belbuca (brand) $11.86 each NDC details & price history
Buccal film · Buccal 450 mcg Belbuca (brand) $16.11 each NDC details & price history
Buccal film · Buccal 600 mcg Belbuca (brand) $17.19 each NDC details & price history
Buccal film · Buccal 750 mcg Belbuca (brand) $18.08 each NDC details & price history
Buccal film · Buccal 900 mcg Belbuca (brand) $18.59 each NDC details & price history
Sublingual tablet · Sublingual 2 mg Generic $0.296 per tablet NDC details & price history
Sublingual tablet · Sublingual 8 mg Generic $0.560 per tablet NDC details & price history
Why it helps: it shows whether the drug itself is cheap or costly, and whether a cash price you are quoted is in a reasonable range. What you pay also depends on your insurance and pharmacy.

Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.

Buprenorphine Brand Names

Buprenorphine has 5 brand names on record: Butrans, Belbuca, Sublocade, Buprenex and others. Butrans, Belbuca, Sublocade and Brixadi are in the FDA’s product directory today; Buprenex is not. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Butrans 2010 Belbuca 2015 Sublocade 2017 Buprenex before 1982, discontinued Brixadi 2023

Who Makes Buprenorphine: Manufacturers and Labelers

32 companies list Buprenorphine products with the FDA. By number of product records, the largest are BioDelivery Sciences International Inc, Braeburn Inc., Bryant Ranch Prepack. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

BioDelivery Sciences International Inc 7 Braeburn Inc. 7 Bryant Ranch Prepack 7 Rhodes Pharmaceuticals LLC 7 Clinical Solutions Wholesale, LLC 6 Amneal Pharmaceuticals NY LLC 5 Aveva Drug Delivery Systems Inc. 5 Ingenus Pharmaceuticals, Llc 5 Knoa Pharma LLC 5 Remedyrepack Inc. 5 Teva Pharmaceuticals USA, Inc. 5 Advagen Pharma Ltd 4 Alvogen Inc. 4 Direct_Rx 3 Hikma Pharmaceuticals USA Inc. 3 A-S Medication Solutions 2 Actavis Pharma, Inc. 2 American Health Packaging 2 AvPAK 2 Camber Pharmaceuticals, Inc. 2 Indivior Inc. 2 Major Pharmaceuticals 2 PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma 2 Redpharm Drug 2

…and 8 more on the FDA NDC directory.

Sources for This Buprenorphine Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Jun 5, 2026, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Buprenorphine.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 39 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
39
Finished products in the current FDA directory
107
Companies listing them (makers, repackagers, distributors)
32
FDA labeler codes behind them ⓘ
35
Linked representative label ⓘ
SpecGx LLC
Linked label effective
Jun 5, 2026
Composite sections available
27
Linked SPL Set ID
b60d514d-a88a-4fa2-a5b0-30ac29e04973
Linked SPL Document ID
d58166b1-982f-4402-af7a-a4afbcbf2e0f
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. SpecGx LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →